verapamil has been researched along with Constipation in 23 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Constipation: Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antihypertensive effect and possible adverse effects of verapamil were assessed in 30 Thai patients with mild to moderate hypertension." | 9.06 | A multicenter study of verapamil in systemic hypertension in Thailand. ( Intharakoses, A; Jeam-Anukulkit, N; Ngarmukos, P; Nontakanun, S; Polsi, Y; Sansanayudth, P; Sitthisook, S; Sriratanaban, A; Tanprasert, P, 1986) |
| "The effectiveness and safety of the beta-adrenergic blocking agent propranolol and the calcium channel antagonist verapamil were compared in 22 patients with chronic stable angina pectoris using a double-blind randomized placebo-controlled crossover protocol." | 9.05 | Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol. ( Bowles, MJ; Davies, AB; Raftery, EB; Subramanian, VB, 1982) |
| "Clinical and exercise responses to therapy with the calcium-channel blocking agent verapamil were assessed in 26 patients with stable exertional angina pectoris using a double-blind, placebo-controlled, randomized crossover study design." | 9.05 | Verapamil therapy for stable exertional angina pectoris. ( Klein, MD; Weiner, DA, 1982) |
| "The clinical responses to 12 months' treatment with verapamil were evaluated in 63 patients with stable and unstable angina pectoris in whom the effectiveness of verapamil had been established in short-term double-blind placebo-controlled randomized clinical trials." | 9.05 | Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials. ( Frishman, WH; Mehta, J; Packer, M; Parodi, O; Scheidt, S; Subramanian, VB, 1982) |
| "In all patients combined, the incidence of constipation (13% vs 2%), dizziness (6% vs 2%), and back pain (3% vs 1%) was higher in patients treated with COER verapamil than with placebo." | 8.81 | Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. ( Anders, RJ; Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| " The effect of dexamethasone in gastrointestinal constipation induced by morphine, verapamil and atropine in mice has been studied." | 7.68 | Dexamethasone modifies morphine-, atropine-, verapamil-induced constipation in mice. ( Calignano, A; Capasso, A; Mancuso, F; Persico, P; Sorrentino, L, 1992) |
| " A long-term, open clinical trial of verapamil therapy was conducted in ninety-three patients with coronary artery disease, selected on the basis of having stable angina pectoris and of being unsuitable for treatment with beta-adrenoceptor blocking drugs." | 7.66 | Verapamil in the long-term treatment of angina pectoris. ( Raftos, J, 1982) |
| " This verapamil formulation can be clinically titrated within a 180 to 540 mg dosing range, permitting effective once-daily administration for the treatment of chronic stable angina." | 6.68 | Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. ( Anders, RJ; Awan, NA; Bultas, J; Cutler, NR; Jhee, SS; Lahiri, A; Sramek, JJ; Woroszylska, M, 1995) |
| "Constipation was the only side-effect reported by those who completed the trial." | 6.67 | [Sustained release verapamil in essential hypertension]. ( Gibor, Y; Nusbaum, M; Yodfat, Y, 1991) |
| "002; multivariate analysis of variance), with 7 significant univariate treatment effects, all favoring COER-verapamil, being noted-pedal edema, polyuria, rapid heart beat or palpitations, hives, muscle cramps, abdominal cramps, and headaches." | 5.09 | Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. ( Anderson, RB; Hollenberg, NK; Williams, GH, 1999) |
| "We conclude that constipation as a result of some calcium channel blockers may be caused by inhibition of colonic motor activity by nifedipine and, to a lesser extent, by verapamil." | 5.08 | Nifedipine and verapamil inhibit the sigmoid colon myoelectric response to eating in healthy volunteers. ( Annese, V; Bassotti, G; Calcara, C; Fiorella, S; Morelli, A; Roselli, P, 1998) |
| "Although constipation is a well-known side effect of calcium channel blockers such as verapamil, this side effect has not been evaluated in a quantitative manner." | 5.07 | Effect of verapamil on human intestinal transit. ( Cohen, S; Krevsky, B; Maurer, AH; Niewiarowski, T, 1992) |
| "The antihypertensive effect and possible adverse effects of verapamil were assessed in 30 Thai patients with mild to moderate hypertension." | 5.06 | A multicenter study of verapamil in systemic hypertension in Thailand. ( Intharakoses, A; Jeam-Anukulkit, N; Ngarmukos, P; Nontakanun, S; Polsi, Y; Sansanayudth, P; Sitthisook, S; Sriratanaban, A; Tanprasert, P, 1986) |
| "The effectiveness and safety of the beta-adrenergic blocking agent propranolol and the calcium channel antagonist verapamil were compared in 22 patients with chronic stable angina pectoris using a double-blind randomized placebo-controlled crossover protocol." | 5.05 | Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol. ( Bowles, MJ; Davies, AB; Raftery, EB; Subramanian, VB, 1982) |
| " The efficacy of verapamil in a dose of 360 mg daily in patients with chronic stable angina pectoris was assessed by quantitative serial treadmill exercise tests and trinitrin consumption." | 5.05 | An objective comparison of verapamil and placebo in chronic stable angina. ( Balasubramanian, V; Raftery, EB, 1982) |
| "Clinical and exercise responses to therapy with the calcium-channel blocking agent verapamil were assessed in 26 patients with stable exertional angina pectoris using a double-blind, placebo-controlled, randomized crossover study design." | 5.05 | Verapamil therapy for stable exertional angina pectoris. ( Klein, MD; Weiner, DA, 1982) |
| "The clinical responses to 12 months' treatment with verapamil were evaluated in 63 patients with stable and unstable angina pectoris in whom the effectiveness of verapamil had been established in short-term double-blind placebo-controlled randomized clinical trials." | 5.05 | Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials. ( Frishman, WH; Mehta, J; Packer, M; Parodi, O; Scheidt, S; Subramanian, VB, 1982) |
| "In all patients combined, the incidence of constipation (13% vs 2%), dizziness (6% vs 2%), and back pain (3% vs 1%) was higher in patients treated with COER verapamil than with placebo." | 4.81 | Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease. ( Anders, RJ; Black, HR; Elliott, WJ; Johnson, MF; White, WB, 2001) |
| " The effect of dexamethasone in gastrointestinal constipation induced by morphine, verapamil and atropine in mice has been studied." | 3.68 | Dexamethasone modifies morphine-, atropine-, verapamil-induced constipation in mice. ( Calignano, A; Capasso, A; Mancuso, F; Persico, P; Sorrentino, L, 1992) |
| " A long-term, open clinical trial of verapamil therapy was conducted in ninety-three patients with coronary artery disease, selected on the basis of having stable angina pectoris and of being unsuitable for treatment with beta-adrenoceptor blocking drugs." | 3.66 | Verapamil in the long-term treatment of angina pectoris. ( Raftos, J, 1982) |
| " This verapamil formulation can be clinically titrated within a 180 to 540 mg dosing range, permitting effective once-daily administration for the treatment of chronic stable angina." | 2.68 | Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. ( Anders, RJ; Awan, NA; Bultas, J; Cutler, NR; Jhee, SS; Lahiri, A; Sramek, JJ; Woroszylska, M, 1995) |
| "Constipation was the only side-effect reported by those who completed the trial." | 2.67 | [Sustained release verapamil in essential hypertension]. ( Gibor, Y; Nusbaum, M; Yodfat, Y, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (60.87) | 18.7374 |
| 1990's | 7 (30.43) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 1 (4.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mehmood, MH | 1 |
| Aziz, N | 1 |
| Ghayur, MN | 1 |
| Gilani, AH | 1 |
| Subramanian, VB | 2 |
| Bowles, MJ | 1 |
| Davies, AB | 1 |
| Raftery, EB | 2 |
| Covinsky, JO | 1 |
| Hamburger, SC | 1 |
| Hedbäck, B | 1 |
| Hermann, LS | 1 |
| Lewis, GR | 2 |
| Raftos, J | 1 |
| Balasubramanian, V | 1 |
| Weiner, DA | 1 |
| Klein, MD | 1 |
| Scheidt, S | 1 |
| Frishman, WH | 1 |
| Packer, M | 1 |
| Mehta, J | 1 |
| Parodi, O | 1 |
| McLeod, J | 1 |
| Cutler, NR | 1 |
| Anders, RJ | 2 |
| Jhee, SS | 1 |
| Sramek, JJ | 1 |
| Awan, NA | 1 |
| Bultas, J | 1 |
| Lahiri, A | 1 |
| Woroszylska, M | 1 |
| Doughty, JC | 1 |
| Donald, AK | 1 |
| Keogh, G | 1 |
| Cooke, TG | 1 |
| Bassotti, G | 1 |
| Calcara, C | 1 |
| Annese, V | 1 |
| Fiorella, S | 1 |
| Roselli, P | 1 |
| Morelli, A | 1 |
| Anderson, RB | 1 |
| Hollenberg, NK | 1 |
| Williams, GH | 1 |
| White, WB | 1 |
| Johnson, MF | 1 |
| Elliott, WJ | 1 |
| Black, HR | 1 |
| Calignano, A | 1 |
| Capasso, A | 1 |
| Persico, P | 1 |
| Mancuso, F | 1 |
| Sorrentino, L | 1 |
| Krevsky, B | 1 |
| Maurer, AH | 1 |
| Niewiarowski, T | 1 |
| Cohen, S | 1 |
| Yodfat, Y | 1 |
| Nusbaum, M | 1 |
| Gibor, Y | 1 |
| Berman, BA | 1 |
| Ross, RN | 1 |
| Ackerman, Z | 1 |
| Lysy, J | 1 |
| Meiner-Lavie, V | 1 |
| Nontakanun, S | 1 |
| Ngarmukos, P | 1 |
| Sitthisook, S | 1 |
| Jeam-Anukulkit, N | 1 |
| Intharakoses, A | 1 |
| Tanprasert, P | 1 |
| Sansanayudth, P | 1 |
| Sriratanaban, A | 1 |
| Polsi, Y | 1 |
| Trohman, RG | 1 |
| Feldman, T | 1 |
| Palomo, AR | 1 |
| Kessler, KM | 1 |
| Myerberg, RJ | 1 |
3 reviews available for verapamil and Constipation
| Article | Year |
|---|---|
Slow channel blockers.
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium Channel Blockers; Chemical Phenomena; Chemistry; Cons | 1983 |
Safety of controlled-onset extended-release verapamil in middle-aged and older patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Back Pain; Constipation; Delayed-Action Preparation | 2001 |
Treating coexisting cardiovascular and pulmonary disease with calcium antagonists.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Asthma, Exercise-Induced; Bronchial Spasm; Calcium; Ca | 1986 |
12 trials available for verapamil and Constipation
| Article | Year |
|---|---|
Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Clinical Trials | 1982 |
Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension.
Topics: Adult; Aged; Constipation; Diastole; Double-Blind Method; Female; Heart Rate; Humans; Hypertension; | 1984 |
An objective comparison of verapamil and placebo in chronic stable angina.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Constipation; Elec | 1982 |
Verapamil therapy for stable exertional angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Constipation; Double-Blind M | 1982 |
Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials.
Topics: Adult; Aged; Angina Pectoris; Calcium Channel Blockers; Clinical Trials as Topic; Constipation; Doub | 1982 |
Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris.
Topics: Adult; Aged; Analysis of Variance; Angina Pectoris; Chronic Disease; Constipation; Delayed-Action Pr | 1995 |
Nifedipine and verapamil inhibit the sigmoid colon myoelectric response to eating in healthy volunteers.
Topics: Adult; Calcium Channel Blockers; Colon, Sigmoid; Constipation; Eating; Gastrointestinal Motility; Hu | 1998 |
Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Calcium Channel Blockers; Constipation; Dou | 1999 |
Effect of verapamil on human intestinal transit.
Topics: Adult; Colon; Constipation; Double-Blind Method; Drug Evaluation; Gastrointestinal Transit; Humans; | 1992 |
[Sustained release verapamil in essential hypertension].
Topics: Blood Pressure; Constipation; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Quali | 1991 |
A multicenter study of verapamil in systemic hypertension in Thailand.
Topics: Adult; Aged; Blood Pressure; Bradycardia; Clinical Trials as Topic; Constipation; Female; Humans; Hy | 1986 |
Long-term results with verapamil in essential hypertension and its influence on serum lipids.
Topics: Blood Pressure; Clinical Trials as Topic; Constipation; Double-Blind Method; Hemodynamics; Humans; H | 1986 |
8 other studies available for verapamil and Constipation
| Article | Year |
|---|---|
Pharmacological basis for the medicinal use of psyllium husk (Ispaghula) in constipation and diarrhea.
Topics: Animals; Arginine Vasopressin; Constipation; Diarrhea; Female; Guinea Pigs; Jejunum; Male; Mice; Mic | 2011 |
The long-term management of hypertension with verapamil.
Topics: Aged; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Constipation; Female; Heart Rate; Hu | 1982 |
Verapamil in the long-term treatment of angina pectoris.
Topics: Angina Pectoris; Bradycardia; Calcium Channel Blockers; Constipation; Coronary Disease; Dose-Respons | 1982 |
Verapamil effective in irritable bowel syndrome?
Topics: Colonic Diseases, Functional; Constipation; Humans; Verapamil | 1983 |
Stercoral perforation with verapamil.
Topics: Aged; Chronic Disease; Constipation; Female; Humans; Hypothyroidism; Intestinal Perforation; Sigmoid | 1994 |
Dexamethasone modifies morphine-, atropine-, verapamil-induced constipation in mice.
Topics: Animals; Atropine; Constipation; Dexamethasone; Dose-Response Relationship, Drug; Drug Interactions; | 1992 |
The association of fecal impaction and verapamil in a patient with scleroderma.
Topics: Adult; Constipation; Fecal Impaction; Female; Humans; Raynaud Disease; Scleroderma, Systemic; Verapa | 1989 |
Verapamil, syncope, and hypertrophic obstructive cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Constipation; Humans; Male; Middle Aged; Syncope; Verapamil | 1986 |